Related Experiment Videos
[SPECT and PET in Parkinson's disease]
1Department of Radiology, National Center Hospital for Mental, Nervous, and Muscular Disorders.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 9, 2000
Summary
Parkinson's disease (PD) shows abnormal brain activity. Dopamine transporter imaging using SPECT may serve as a useful marker for tracking PD motor severity.
Area of Science:
- Neuroimaging
- Neurology
- Molecular Imaging
Context:
- Parkinson's disease (PD) involves functional abnormalities in basal ganglia-thalamocortical circuits.
- Cerebral blood flow and glucose metabolism are altered in PD patients.
Purpose:
- To evaluate the utility of dopamine transporter imaging in Parkinson's disease.
- To assess D2 receptor status and dopamine transporter levels in PD.
Summary:
- SPECT and PET imaging reveal functional changes in PD.
- [123I] IBF SPECT and [11C] raclopride PET show promise for assessing D2 receptor status.
- SPECT imaging demonstrates significant differences in dopamine transporters between PD patients and controls.
Impact:
- Dopamine transporter levels correlate with motor severity in PD.
- SPECT measures of dopamine transporters may be a valuable biomarker for PD progression.
- Distinguishing PD from multiple system atrophy based on D2 receptor density is possible.